Joint Clinical Trials Office
A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients with Dravet Syndrome
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 30, 2025
Cold Snare Endoscopic Mucosal Resection of Duodenal Adenomas ≥10 mm: A prospective cohort
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 30, 2025
A Global, Randomized, Open-label, Multicenter, Phase 2b/3 Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-1)
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 8, 2025
Efficacy of the COronary SInus Reducer in Patients with Refractory Angina II (COSIRA-II)
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 15, 2025
Endocardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment: A 26-Week (with 26 Week Extension) Phase 2b Randomized, Multi-Center, Double-Blind, Sham Controlled Study to Evaluate Efficacy and Safety (The EXACT-2 Trial)
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 15, 2025
The Magenta Elevate™ High-Risk PCI Pivotal Study (Elevate III)
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 15, 2025
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 7, 2025
A Phase III, Open-label, Randomised Study of Osimertinib With or Without Dato-DXd as First-line Treatment in Participants With Epidermal Growth Factor Receptor Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 7, 2025
Phase 1 Trial of CA-4948 in Combination with Pembrolizumab to Overcome Resistance to PD-1/PD-L1 Blockade in Metastatic Urothelial Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 20, 2025
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd)
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 8, 2025